Trade Names: | |
Synonyms: | |
Status: | Approved (1966) |
Entry Type: | Small molecule |
Molecule Category: | Parent |
ATC: | M04AA01 |
UNII: | 63CZ7GJN5I |
InChI Key | OFCNXPDARWKPPY-UHFFFAOYSA-N |
---|---|
Smile | |
InChI |
|
Property Name | Value |
---|---|
Molecular Formula | C5H4N4O |
Molecular Weight | 136.11 |
AlogP | -0.4 |
Hydrogen Bond Acceptor | 3.0 |
Hydrogen Bond Donor | 2.0 |
Number of Rotational Bond | 0.0 |
Polar Surface Area | 74.43 |
Molecular species | NEUTRAL |
Aromatic Rings | 0.0 |
Heavy Atoms | 10.0 |
Action | Mechanism of Action | Reference |
---|---|---|
INHIBITOR | Xanthine dehydrogenase inhibitor | FDA |
Primary Target | |
---|---|
xanthine dehydrogenase |
Targets | EC50(nM) | IC50(nM) | Kd(nM) | Ki(nM) | Inhibition(%) | |
---|---|---|---|---|---|---|
Enzyme
Hydrolase
|
- | 23900 | - | - | 76 | |
Enzyme
Oxidoreductase
|
- | 4-50150 | 1 | 100-7300 | 95-100 | |
Secreted protein
|
- | 23900 | - | - | 76 | |
Transporter
Electrochemical transporter
SLC superfamily of solute carriers
SLC21/SLCO family of organic anion transporting polypeptides
|
- | - | - | - | 11-84 | |
Transporter
Electrochemical transporter
SLC superfamily of solute carriers
SLC22 family of organic cation and anion transporters
|
- | - | - | - | 8 |
Mesh Heading | Maximum Phase | Mesh ID | Reference |
---|---|---|---|
Bipolar Disorder | 3 | D001714 | ClinicalTrials |
Hypertension | 3 | D006973 | ClinicalTrials |
Cardiovascular Diseases | 3 | D002318 | ClinicalTrials |
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 | D054198 | ClinicalTrials |
Sprains and Strains | 3 | D013180 | ClinicalTrials |
Hernias, Diaphragmatic, Congenital | 3 | D065630 | ClinicalTrials |
Hyperuricemia | 3 | D033461 | ClinicalTrials |
Obesity | 3 | D009765 | ClinicalTrials |
Colitis, Ulcerative | 3 | D003093 | ClinicalTrials |
Heart Diseases | 3 | D006331 | ClinicalTrials |
Diabetes Mellitus, Type 2 | 3 | D003924 | ClinicalTrials |
Lymphoma, Non-Hodgkin | 3 | D008228 | ClinicalTrials |
Tumor Lysis Syndrome | 3 | D015275 | ClinicalTrials |
Peritoneal Neoplasms | 2 | D010534 | ClinicalTrials |
Ovarian Neoplasms | 2 | D010051 | ClinicalTrials |
Kidney Calculi | 2 | D007669 | ClinicalTrials |
Metabolic Syndrome | 2 | D024821 | ClinicalTrials |
Heart Failure | 2 | D006333 | ClinicalTrials |
Heart Failure | 2 | D006333 | ClinicalTrials |
Leukemia, Lymphocytic, Chronic, B-Cell | 2 | D015451 | ClinicalTrials |
Myelodysplastic Syndromes | 2 | D009190 | ClinicalTrials |
Leukemia, Myeloid, Acute | 2 | D015470 | ClinicalTrials |
Diabetes Mellitus | 2 | D003920 | ClinicalTrials |
Multiple Myeloma | 2 | D009101 | ClinicalTrials |
Leishmaniasis | 2 | D007896 | ClinicalTrials |
Hand-Foot Syndrome | 2 | D060831 | ClinicalTrials |
Essential Hypertension | 2 | D000075222 | ClinicalTrials |
Renal Insufficiency, Chronic | 2 | D051436 | ClinicalTrials |
Myeloproliferative Disorders | 2 | D009196 | ClinicalTrials |
Angina, Stable | 2 | D060050 | ClinicalTrials |
Fallopian Tube Neoplasms | 2 | D005185 | ClinicalTrials |
Leukemia, Biphenotypic, Acute | 1 | D015456 | ClinicalTrials |
Inflammatory Bowel Diseases | 1 | D015212 | ClinicalTrials |
Tuberculosis | 1 | D014376 | ClinicalTrials |
Osteoarthritis | 1 | D010003 | ClinicalTrials |
Side effects | Relative Frequency (%) | Labels | |
---|---|---|---|
Skin and subcutaneous tissue disorders Rash maculo-papular | 10.0 | ||
Skin and subcutaneous tissue disorders Dermatitis | 1.5 | ||
Skin and subcutaneous tissue disorders Rash | 1.5 | ||
Gastrointestinal disorders Nausea | 1.3 | ||
Gastrointestinal disorders Vomiting | 1.2 |
Resources | Reference |
---|---|
CAS NUMBER | 315-30-0 |
ChEBI | 40279 |
ChEMBL | CHEMBL1467 |
DrugBank | DB00437 |
DrugCentral | 124 |
EPA CompTox | DTXSID4022573 |
FDA SRS | 63CZ7GJN5I |
Human Metabolome Database | HMDB0014581 |
Guide to Pharmacology | 6795 |
PharmGKB | PA448320 |
PubChem | 135401907 |
SureChEMBL | SCHEMBL4627 |
ZINC | ZINC000013298313 |